Arno Therapeutics, Inc. (ARNI)

Market Cap	9.87K
Revenue (ttm)	n/a
Net Income (ttm)	-13.70M
Shares Out	49.35M
EPS (ttm)	-0.38
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,460
Average Volume	7,506
Open	0.0002
Previous Close	0.0002
Day's Range	0.0002 - 0.0002
52-Week Range	0.0000 - 0.0002
Beta	-18.73
RSI	40.61
Earnings Date	n/a

About Arno Therapeutics

Arno Therapeutics, Inc., a biopharmaceutical company, develops products for the treatment of cancer and other life threatening diseases. The company’s product development pipeline includes Onapristone, a type 1 anti-progestin hormone blocker that is in Phase I/II clinical study for the treatment of breast, endometrial, and others solid tumors in post-menopausal women; and advanced castration-resistant prostate cancer in men. Its product development pipeline also consists of AR-12, an orally available cancer treatment, which has completed Phase ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 4
• Stock Exchange: OTCMKTS
• Ticker Symbol: ARNI